{"transactions":[{"id":957262,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":70755,"kind":"person","name":"Bhowmick Neil","position":1,"cik":"0001872210","reported_name":"Bhowmick Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"COMMON STOCK","published_at":"2025-12-30T16:10:14.000Z","date":"2025-10-08","kind":"grant","planned":false,"acquired":true,"shares":171756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 171,756 restricted stock units (\"RSUs\") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 171,756 RSUs are scheduled to vest on the on the first anniversary of the grant date which is October 8, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of (1) 1,135,317 shares of common stock and (2) 176,422 RSUs which remain subject to vesting."}],"balance_after":1311739,"source":{"system":"sec-edgar","filing":"0001493152-25-029601","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872210/000149315225029601/ownership.xml","form_type":"4"}},{"id":959826,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":70897,"kind":"person","name":"Bae Hyun W.","position":1,"cik":"0001988551","reported_name":"Bae Hyun W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK","published_at":"2025-12-23T06:03:35.000Z","date":"2025-10-08","kind":"grant","planned":false,"acquired":true,"shares":19084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents 19,084 RSUs issued to the Reporting Person under the Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Consists of (i) 54,286 shares of common stock and (ii) 19,084 RSUs which remain subject to vesting."}],"balance_after":73370,"source":{"system":"sec-edgar","filing":"0001493152-25-028895","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1988551/000149315225028895/ownership.xml","form_type":"4"}},{"id":959825,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":70897,"kind":"person","name":"Bae Hyun W.","position":1,"cik":"0001988551","reported_name":"Bae Hyun W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK","published_at":"2025-12-23T06:03:35.000Z","date":"2025-09-16","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 10,000 restricted stock units (\"RSUs\") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan (the \"Plan\"). The 10,000 RSUs were granted on September 16, 2024, in conjunction with the Issuer's initial public offering (IPO), and vest annually in three substantially equal installments commencing on the anniversary date of the IPO."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of (i) 47,620 shares of common stock and (ii) 6,666 RSUs which remain subject to vesting."}],"balance_after":54286,"source":{"system":"sec-edgar","filing":"0001493152-25-028895","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1988551/000149315225028895/ownership.xml","form_type":"4"}},{"id":986738,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":36741,"kind":"person","name":"Singhvi Rahul","position":1,"cik":"0001322731","reported_name":"Singhvi Rahul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK","published_at":"2025-11-26T22:26:43.000Z","date":"2025-10-08","kind":"grant","planned":false,"acquired":true,"shares":19084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 19,084 restricted stock units (\"RSUs\") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of 49,204 RSUs which remain subject to vesting."}],"balance_after":49204,"source":{"system":"sec-edgar","filing":"0001493152-25-025203","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322731/000149315225025203/ownership.xml","form_type":"4"}},{"id":987305,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":72525,"kind":"person","name":"Murali Ramachandran","position":1,"cik":"0001870016","reported_name":"Murali Ramachandran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Research and Development"}}],"security":"COMMON STOCK","published_at":"2025-11-26T18:50:34.000Z","date":"2025-10-08","kind":"grant","planned":false,"acquired":true,"shares":152672,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 152,672 restricted stock units (\"RSUs\") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 152,672 RSUs are scheduled to vest in full on the first anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of (1) 142,191 shares of common stock and (2) 157,338 RSUs which remain subject to vesting."}],"balance_after":299529,"source":{"system":"sec-edgar","filing":"0001493152-25-025224","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870016/000149315225025224/ownership.xml","form_type":"4"}},{"id":986516,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":72501,"kind":"person","name":"Keyoung Hansoo Michael","position":1,"cik":"0001824764","reported_name":"Keyoung Hansoo Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK","published_at":"2025-11-26T17:27:13.000Z","date":"2025-10-08","kind":"grant","planned":false,"acquired":true,"shares":19084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents 19,084 RSUs) issued to the Reporting Person under the Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Consists of (i) 3,334 shares of common stock and (ii) 25,750 RSUs which remain subject to vesting."}],"balance_after":29084,"source":{"system":"sec-edgar","filing":"0001493152-25-025205","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1824764/000149315225025205/ownership.xml","form_type":"4"}},{"id":986515,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":72501,"kind":"person","name":"Keyoung Hansoo Michael","position":1,"cik":"0001824764","reported_name":"Keyoung Hansoo Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK","published_at":"2025-11-26T17:27:13.000Z","date":"2025-09-16","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 10,000 restricted stock units (\"RSUs\") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan (the \"Plan\"). The 10,000 RSUs were granted on September 16, 2024, in conjunction with the Issuer's initial public offering (IPO), and grant in substantially equal installments on the anniversary date of the IPO."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of (i) 3,334 shares of common stock and (ii) 6,666 RSUs which remain subject to vesting."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001493152-25-025205","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824764/000149315225025205/ownership.xml","form_type":"4"}},{"id":986506,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":72498,"kind":"person","name":"Samuelson Doug","position":1,"cik":"0001943326","reported_name":"Samuelson Doug","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"COMMON STOCK","published_at":"2025-11-26T17:24:13.000Z","date":"2025-10-08","kind":"grant","planned":false,"acquired":true,"shares":152672,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 152,672 restricted stock units (\"RSUs\") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 152,672 RSUs are scheduled to vest in full on the first anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of (1) 140,367 shares of common stock and (2) 152,672 RSUs which remain subject to vesting."}],"balance_after":293039,"source":{"system":"sec-edgar","filing":"0001493152-25-025198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1943326/000149315225025198/ownership.xml","form_type":"4"}},{"id":986630,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":72510,"kind":"person","name":"Yu John S","position":1,"cik":"0001550545","reported_name":"Yu John S","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and Chairman"}}],"security":"COMMON STOCK","published_at":"2025-11-26T17:24:11.000Z","date":"2025-10-08","kind":"grant","planned":false,"acquired":true,"shares":190840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 190,840 restricted stock units (\"RSUs\") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 190,840 RSUs are scheduled to vest in full on the first anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of (1) 34,599 shares of common stock (2) 195,506 RSUs which remain subject to vesting."}],"balance_after":230105,"source":{"system":"sec-edgar","filing":"0001493152-25-025197","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1550545/000149315225025197/ownership.xml","form_type":"4"}},{"id":1176780,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":70755,"kind":"person","name":"Bhowmick Neil","position":1,"cik":"0001872210","reported_name":"Bhowmick Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"COMMON STOCK","published_at":"2025-04-07T08:30:18.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 14,000 restricted stock units (\"RSUs\") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 14,000 RSUs are scheduled to vest in one third increments on each of 01/01/2025, 09/16/2025, and 09/16/2026. Accordingly, 4,667 RSUs have vested as of the date hereof."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of (1) 1,130,650 shares of common stock and (2) 9,333 RSUs which remain subject to vesting."}],"balance_after":1139983,"source":{"system":"sec-edgar","filing":"0001641172-25-002927","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872210/000164117225002927/ownership.xml","form_type":"4"}},{"id":1249897,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":72525,"kind":"person","name":"Murali Ramachandran","position":1,"cik":"0001870016","reported_name":"Murali Ramachandran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Research and Development"}}],"security":"COMMON STOCK","published_at":"2025-02-24T18:52:11.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 14,000 restricted stock units (\"RSUs\") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 14,000,000 RSUs are scheduled to vest in one third increments on each of 01/01/2025, 09/16/2025, and 09/16/2026. Accordingly, 4,667 RSUs have vested as of the date hereof."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of (1) 137,724 shares of common stock and (2) 9,333 RSUs which remain subject to vesting."}],"balance_after":147057,"source":{"system":"sec-edgar","filing":"0001493152-25-008106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870016/000149315225008106/ownership.xml","form_type":"4"}},{"id":1249022,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":72510,"kind":"person","name":"Yu John S","position":1,"cik":"0001550545","reported_name":"Yu John S","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and Chairman"}}],"security":"COMMON STOCK","published_at":"2025-02-24T18:51:39.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 14,000 restricted stock units (\"RSUs\") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 14,000 RSUs are scheduled to vest in one third increments on each of 01/01/2025, 09/16/2025, and 09/16/2026. Accordingly, 4,667 RSUs have vested as of the date hereof."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of (1) 5,346,504 shares of common stock and (2) 9,334 RSUs which remain subject to vesting."}],"balance_after":5355838,"source":{"system":"sec-edgar","filing":"0001493152-25-008105","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1550545/000149315225008105/ownership.xml","form_type":"4"}},{"id":1352874,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":72525,"kind":"person","name":"Murali Ramachandran","position":1,"cik":"0001870016","reported_name":"Murali Ramachandran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Research and Development"}}],"security":"COMMON STOCK","published_at":"2024-11-25T20:30:12.000Z","date":"2024-11-25","kind":"purchase","planned":false,"acquired":true,"shares":200,"price":1.59,"value":318.0,"ownership":{"direct":true},"balance_after":133057,"source":{"system":"sec-edgar","filing":"0001493152-24-047695","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870016/000149315224047695/ownership.xml","form_type":"4"}},{"id":1352275,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":72498,"kind":"person","name":"Samuelson Doug","position":1,"cik":"0001943326","reported_name":"Samuelson Doug","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"COMMON STOCK","published_at":"2024-11-25T06:03:39.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":1.5,"value":3750.0,"ownership":{"direct":true},"balance_after":60796,"source":{"system":"sec-edgar","filing":"0001493152-24-047526","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1943326/000149315224047526/ownership.xml","form_type":"4"}},{"id":1355562,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":72510,"kind":"person","name":"Yu John S","position":1,"cik":"0001550545","reported_name":"Yu John S","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and Chairman"}}],"security":"COMMON STOCK","published_at":"2024-11-21T21:53:44.000Z","date":"2024-11-20","kind":"purchase","planned":false,"acquired":true,"shares":4000,"price":1.44,"value":5760.0,"ownership":{"direct":true},"balance_after":5341837,"source":{"system":"sec-edgar","filing":"0001493152-24-047261","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1550545/000149315224047261/ownership.xml","form_type":"4"}}]}